Back to homepage

Tag "ospemifene"

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies

Authors: Ana Rosa Jurado López MD, PhD, Francisca Molero Rodríguez MD

The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia.

More

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies

Authors: Félix Lugo Salcedo MD, Zuramis Estrada Blanco MD

This article reports the clinical course of two women with dyspareunia preventing sexual intercourse who were treated with ospemifene and laser therapy.

More

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Authors: Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.

More

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study

Authors: Silvia Pilar González Rodríguez MD, PhD

This case study reports the experience of a postmenopausal woman with VVA who required escalation from local therapy and presented CVD risk factors (family history and hypertension).

More

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Authors: Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

More